Effect of 1-phenyl-3-(2-thiazolyl)-2-thiourea, a dopamine beta-hydroxylase inhibitor on morphine analgesia, tolerance and physical dependence.
D000109:Acetylcholine / Q000378:metabolism; D000698:Analgesia; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002794:Choline / Q000378:metabolism; D002849:Chromatography, Gas; D003300:Copper / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors*; D004357:Drug Synergism; D004361:Drug Tolerance / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D009020:Morphine / Q000378:metabolism / Q000494:pharmacology*; D009021:Morphine Dependence / Q000188:drug therapy*; D009270:Naloxone / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D010670:Phenylthiourea / Q000494:pharmacology* / Q000627:therapeutic use; D012701:Serotonin / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced; D013997:Time Factors
D012701:Serotonin; D009270:Naloxone; D010670:Phenylthiourea; D009020:Morphine; D003300:Copper; D004299:Dopamine beta-Hydroxylase; D002794:Choline; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine